Integra LifeSciences Holdings Corporation IART R2KR3KPHARMA
Company Overview
Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical, ear, nose, throat, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates through Codman Specialty Surgical and Tissue Technologies segments. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment. It also offers after-market services; surgical headlamps and instrumentation; instrument patterns and surgical and lighting products to hospitals, surgery centers, dental, podiatry, and veterinary offices. In addition, the company provides treatment of acute wounds, such as burns; chronic wounds, including diabetic foot ulcers; and surgical tissue repair applications, including hernia reinforcement, tendon protection, and peripheral nerve repair. Further, it offers skin and wound repair, plastics and surgical reconstruction products, and nerve and tendon repair products. Additionally, the company is involved in the ear, nose, and throat business that includes instrumentation, balloon technologies for sinus dilation and eustachian tube dilation, and surgical navigation systems. It offers its products directly through various salesforces and other distribution channels to the hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, and health care providers in the United States, Europe, the Asia Pacific, and internationally. Integra LifeSciences Holdings Corporation was formerly known as Integra LifeSciences Corp. and changed its name to Integra LifeSciences Holdings Corporation in June 1995. Integra LifeSciences Holdings Corporation was incorporated in 1989 and is headquartered in Princeton, New Jersey.
Why Investors Should Care
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $1.64B (+1.5% YoY); net profit $-516.47M.
- Trailing 12 Months Year-on-year growth — revenue +0.8%.
- 5-Year Trend Long-term compounding — revenue CAGR 5.5%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 5.53% |
| 1 Year: | 0.80% |
Stock Price Performance
| 1 Year: | +18.41% |
| 6 Months: | +71.84% |
| 3 Months: | -1.59% |
| 1 Month: | -2.22% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMAAbove
- RSI (14)44.24 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | IART Integra LifeSciences Holdings Corporation R2KR3KPHARMA | 16.72 | -185.78 | $1.30B | 0.00% | -15.68% | -0.70% | 5.53% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | 258.64M | 282.16M | 278.83M | 368.60M | 357.08M | 366.19M | 365.85M | 383.31M | 359.69M | 383.64M | 379.10M | 395.13M | 354.32M | 258.67M | 370.23M | 388.65M | 360.07M | 389.99M | 386.86M | 376.64M | 397.81M | 385.19M | 380.85M | 381.27M | 382.42M | 368.87M | 418.18M | 380.83M | 382.65M | 415.61M | 402.06M | 434.93M | 391.92M | 418.76M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 188.22M | 206.27M | 195.07M | 214.06M | 174.94M | - |
| Gross Profit | 140.30M | 151.16M | 152.00M | 159.74M | 161.00M | 170.24M | 172.05M | 183.17M | 177.08M | 220.43M | 212.86M | 228.62M | 222.61M | 236.85M | 230.78M | 239.97M | 236.46M | 245.66M | 220.85M | 153.19M | 235.42M | 241.58M | - | - | - | - | - | - | - | - | - | - | - | - | 194.43M | 209.33M | 206.99M | 220.87M | 216.98M | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 209.93M | 210.64M | 195.23M | 197.82M | 205.51M | - |
| Operating Income | 9.99M | - | 22.10M | 22.38M | 30.09M | - | 9.96M | 16.98M | 10.64M | - | 25.58M | 27.63M | 23.68M | - | 32.31M | 45.96M | -20.59M | - | 27.10M | 14.08M | 57.54M | - | 30.71M | 51.85M | 56.44M | 46.16M | 59.87M | 65.05M | 36.38M | 12.50M | 26.59M | 3.96M | -3.03M | -8.15M | -15.50M | -1.31M | 11.76M | 23.04M | 11.47M | 19.29M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 25.97M | -472.22M | 54.42M | 66.41M | 58.49M | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 18.82M | 21.04M | 22.73M | 23.67M | 22.46M | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -30.04M | -530.95M | -6.82M | 4.31M | -2.41M | - |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -4.74M | -46.88M | -1.42M | 6.01M | 2.21M | - |
| Net Income | -31.88M | 14.98M | 13.42M | 12.76M | 20.14M | 28.25M | 6.39M | 10.84M | 3.16M | 44.35M | 10.99M | 11.38M | 13.29M | 25.14M | 32.76M | 29.74M | -27.61M | 15.32M | 9.18M | -369.00K | 32.34M | 92.74M | 45.39M | 35.07M | 43.23M | 32.90M | 44.79M | 49.91M | 24.23M | 4.18M | 19.50M | -3.28M | -12.40M | -10.70M | -25.29M | -484.07M | -5.40M | -1.70M | -4.62M | 4.48M |
| Diluted EPS | -0.45 | 0.20 | 0.18 | 0.16 | 0.25 | 0.35 | 0.08 | 0.14 | 0.04 | 0.56 | 0.14 | 0.14 | 0.15 | 0.29 | 0.38 | 0.34 | -0.32 | 0.18 | 0.11 | 0.00 | 0.38 | 1.09 | 0.53 | 0.41 | 0.51 | 0.39 | 0.54 | 0.60 | 0.29 | 0.05 | 0.24 | -0.04 | -0.16 | -0.14 | -0.33 | -6.31 | -0.07 | -0.02 | -0.06 | 0.06 |
| R&D Expense | 13.94M | - | 14.45M | 14.68M | 15.12M | - | 15.49M | 15.75M | 15.03M | - | 18.32M | 19.11M | 20.31M | - | 18.32M | 17.63M | 19.00M | - | 20.82M | 14.93M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 654.60M | 682.49M | 732.07M | 780.08M | 830.87M | 696.83M | 796.72M | 882.73M | 992.08M | 1.19B | 1.47B | 1.52B | 1.37B | 1.54B | 1.56B | 1.54B | 1.61B | 1.64B |
| Gross Profit | - | - | - | - | - | - | 493.77M | 556.19M | 642.99M | 752.73M | 900.95M | 952.88M | 851.03M | - | - | - | - | - |
| Operating Income | 47.41M | 97.82M | 98.69M | 54.91M | 73.78M | 35.37M | 67.86M | 79.59M | 115.34M | 44.80M | 111.00M | 93.76M | 151.37M | 197.23M | 238.92M | 111.53M | 28.41M | -493.37M |
| Net Income | 27.73M | 50.95M | 65.67M | 27.99M | 41.20M | -21.07M | 34.00M | -3.52M | 74.56M | 64.74M | 60.80M | 50.20M | 133.89M | 169.07M | 180.55M | 67.74M | -6.94M | -516.47M |
| Diluted EPS | 0.96 | 1.74 | 2.17 | 0.95 | 1.44 | -0.74 | 0.52 | -0.05 | 0.94 | 0.82 | 0.72 | 0.58 | 1.57 | 1.98 | 2.16 | 0.84 | -0.09 | -6.74 |
| R&D Expense | 60.49M | 44.28M | 48.11M | 51.45M | 51.01M | 42.62M | 43.56M | 50.90M | 58.16M | 63.45M | 78.04M | - | - | - | - | - | - | - |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 940.10M | 1.02B | 1.14B | 1.16B | 1.19B | 1.59B | 1.77B | 1.81B | 3.21B | 3.11B | 3.30B | 3.62B | - | 3.89B | 3.78B | 4.04B | 3.60B |
| Current Assets | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.16B | 1.06B | 1.08B | 1.16B |
| Cash & Equivalents | 57.34M | 183.55M | 71.89M | 128.76M | 100.81M | 96.94M | 120.61M | 71.73M | 48.13M | 102.06M | 174.94M | 138.84M | 198.91M | 470.17M | - | 456.66M | 276.40M | 246.38M | 235.05M |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 324.58M | 389.61M | 429.09M | 492.74M |
| Receivables | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 263.46M | 259.33M | 272.37M | 278.85M |
| Total Liabilities | - | - | 495.22M | 519.17M | 651.47M | 645.82M | 526.05M | 883.10M | 1.02B | 968.29M | 2.25B | 1.73B | 1.89B | 2.10B | - | 2.09B | 2.19B | 2.49B | 2.56B |
| Current Liabilities | - | - | 156.73M | 201.86M | 101.87M | 106.93M | 119.38M | 126.03M | 139.13M | 123.60M | 348.91M | 262.55M | 331.31M | 401.01M | - | 320.91M | 306.98M | 922.13M | 455.98M |
| Long Term Debt | - | - | - | - | - | - | - | - | - | - | - | 900.00M | 877.50M | 877.50M | - | 1.41B | 1.49B | 1.20B | 1.73B |
| Total Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.62B | 1.68B | 1.98B | 2.03B |
| Total Equity | 287.59M | 372.31M | 444.88M | 499.96M | 492.64M | 517.77M | 666.09M | 704.32M | 751.44M | 839.67M | 962.31M | 1.38B | 1.42B | 1.51B | - | 1.80B | 1.59B | 1.55B | 1.04B |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 90.48M | 90.92M | 91.61M | 92.29M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 72.59M | 143.24M | 105.57M | 104.33M | 59.10M | 53.27M | 83.56M | 104.85M | 116.41M | 114.54M | 199.68M | 231.43M | 203.83M | 312.43M | 264.47M | 139.96M | 129.38M | 50.38M |
| Investing Cash Flow | -100.28M | -88.35M | -42.32M | -190.38M | -79.28M | -50.30M | -363.32M | -372.01M | -42.62M | -1.22B | -49.70M | -162.67M | -68.07M | -161.44M | -58.58M | -94.18M | -390.81M | -108.06M |
| Financing Cash Flow | 153.54M | -171.34M | -1.57M | 60.14M | 11.75M | 19.02M | 238.68M | 248.14M | -15.12M | 1.17B | -180.87M | -8.77M | 121.62M | -98.23M | -251.95M | -229.93M | 237.86M | 28.34M |
| Capital Expenditure | -13.40M | -25.24M | -37.14M | -38.42M | -69.03M | -42.30M | -38.34M | -33.41M | -47.33M | -43.50M | -77.74M | -69.54M | -38.89M | -48.02M | -42.34M | -66.86M | -104.42M | -81.44M |
| Free Cash Flow | 59.19M | 118.00M | 68.43M | 65.90M | -9.93M | 10.97M | 45.23M | 71.44M | 69.08M | 71.04M | 121.94M | 161.90M | 164.94M | 264.40M | 222.13M | 73.09M | 24.96M | -31.05M |
| Share Buybacks | 0 | 0 | 31.28M | 83.46M | 0 | 0 | - | - | - | - | 0 | 0 | 100.00M | 0 | 125.00M | 275.00M | 52.47M | 221.00K |
Ratios (Annual)
Figures in %.
| Metric | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | 62.0% | 63.0% | 64.8% | 63.3% | 61.2% | 62.8% | 62.0% | - | - | - | - | - |
| Operating Margin % | 7.2% | 14.3% | 13.5% | 7.0% | 8.9% | 5.1% | 8.5% | 9.0% | 11.6% | 3.8% | 7.5% | 6.2% | 11.0% | 12.8% | 15.3% | 7.2% | 1.8% | -30.2% |
| Net Margin % | 4.2% | 7.5% | 9.0% | 3.6% | 5.0% | -3.0% | 4.3% | -0.4% | 7.5% | 5.4% | 4.1% | 3.3% | 9.8% | 11.0% | 11.6% | 4.4% | -0.4% | -31.6% |
| ROE % | 7.4% | 11.5% | 13.1% | 5.7% | 8.0% | -3.2% | 4.8% | -0.5% | 8.9% | 6.7% | 4.4% | 3.5% | 8.8% | - | 10.0% | 4.3% | -0.4% | -49.5% |
| ROCE % | - | 12.5% | 12.1% | 5.3% | 7.0% | 3.3% | 4.6% | 4.9% | 6.8% | 1.6% | 3.9% | 3.2% | 4.7% | - | 6.7% | 3.2% | 0.9% | -15.7% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 13.74% | 10.68M | $180.45M |
| 2 | Rubric Capital Management LP | 9.97% | 7.75M | $130.96M |
| 3 | Invesco Ltd. | 4.82% | 3.75M | $63.33M |
| 4 | Vanguard Portfolio Management LLC | 4.81% | 3.74M | $63.22M |
| 5 | Morgan Stanley | 4.62% | 3.59M | $60.69M |
| 6 | Fuller & Thaler Asset Management Inc. | 4.42% | 3.44M | $58.03M |
| 7 | Paradigm Capital Management | 4.42% | 3.44M | $58.09M |
| 8 | State Street Corporation | 3.79% | 2.95M | $49.77M |
| 9 | Vanguard Capital Management LLC | 3.79% | 2.95M | $49.76M |
| 10 | Neuberger Berman Group, LLC | 3.04% | 2.36M | $39.94M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for IART
Integra executives will speak at two healthcare conferences - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxPSWhPMkRFbVlwT3M1dE9kemdlYnFoQ0VlTllNeXQ2Zzh6ZmFsNFhrTUg2X0c1cFJJaDk2Y1FValhSNEtCOGFrMXBJeXJaclV5dFQzcmxXZjBaOEFOeE5KeGVJZmZBTEhjbDVpRUllTFo1LVk4dUFJWXA1S1hhYnpPUGJiU3VhTE9nbEJOaU…
IART Stock Surges 52.1% in a Year: What's Driving the Rally? - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMikAFBVV95cUxNOTlVSVFkOXlXd0V5WG51emRKRzFkalRpYnN4cDQ0REJGaUhDMDFlZHhybG43WGtJai04VFhmS3lHTEtxNGJLNDFhX251SXVVal8xd3g2VW5zbEFaRHZsbC1KMzhtZWwzbHl5OTNJWFg4MHFJY1dsS01lcXRRTnhLUmx5TGRON2c4VFNvMV…
Integra LifeSciences: Strong Q2 2026 Results Support Recovery Thesis (NASDAQ:IART) - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMirAFBVV95cUxPMGNHWTJRSG1UdVVNWmxDQW14ZzlhZTJhcUJ0UGxwa19PLThtOVBxMUw0bXU1Q1hsc1dBOTloaW44emxnUGlYY2lNVEpvdXd6YUNyYmhNTHRJR3luS1BYSm10R09HWjlwT3VscWJmTWZnc2c3UUhsdE5EZ3VQSUFyejByTFA5dzlTSjViWD…
IART - Integra Lifesciences Holdings Corp Stock Price and Quote - Finviz
<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTFBGTFRRWFVBMk15UlFRRkRsS2RiNk56MjFhclYxVVdvNWF0ejVyMTBkaW13d1cxLUNuQm5qRmI2UHZsazgtTmc?oc=5" target="_blank">IART - Integra Lifesciences Holdings Corp Stock Price and Quote</a> …
Why Integra LifeSciences (IART) is a Top Value Stock for the Long-Term - Eastern Progress
<a href="https://news.google.com/rss/articles/CBMi5AFBVV95cUxQaWM4OHVHQzlGaXQ2czh0Y3lOSFlJbmRkVmlHWjJuSU9xeXlzQ0ZVZ0hTdjdJZmEtWXVRN29JLS1TZ05MaWJFOGQ3WHV1Tjhyd3hOT3RCVDRXRHFsd20tSVpzTzBET05TVF9SUmhyNHkzQ1NRaHB0QW1vWi1vcV9HZTQ0Nkdac0ZDZ3RjOG…
Integra LifeSciences’s (NASDAQ:IART) Q2 CY2026 Earnings Results: Revenue In Line With Expectations - StockStory
<a href="https://news.google.com/rss/articles/CBMi5wFBVV95cUxPZWhRNHFnVW8tU2wtODNfc1RSejNTUF9XYklIV2oweGIwUmtrS0FpcW9ma2ViX0ZTZ0t5S0FLQjY5ZDBFakEyaUlVdmFnTzR5UWZHZDF0amJEc1VPN2ttaHBucmlZVG1tVHZpVTFoWjNqLThmdG1JTkVmMlA3WU5qZzUyWmVTNzlpQktnZF…
IART — Frequently Asked Questions
What is the current share price of Integra LifeSciences Holdings Corporation (IART)?
As of 2026-09-07 16:24 PDT, Integra LifeSciences Holdings Corporation (IART) trades at $16.72 on NasdaqGS. Its 52-week range is $8.90 to $19.85.
What is the market capitalisation of IART?
Integra LifeSciences Holdings Corporation (IART) has a market capitalisation of $1.30B on NasdaqGS.
What is the P/E ratio of IART?
IART trades at a trailing price-to-earnings (P/E) ratio of -185.78. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 1.29.
What is the return on equity (ROE) of IART?
IART has a return on equity (ROE) of -0.70%. Its return on capital employed (ROCE) is -15.68%.
Is IART a good stock to buy?
This page provides a data-driven analysis of Integra LifeSciences Holdings Corporation (IART), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.